Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus
AbstractInsulin therapy is indispensable for achieving glycemic control in all patients with type 1 diabetes mellitus and many patients with type 2 diabetes mellitus. Insulin injections are associated with negative connotations in patients owing to administration discomfort and adverse effects such as hypoglycemia and weight gain. Insulin administered orally can overcome these limitations by providing a convenient and eff ective mode of delivery with a potentially lower risk of hypoglycemia. Oral insulin mimics the physiologic process of insulin secretion, absorption into the portal circulation, and subsequent peripheral...
Source: Drugs - August 14, 2023 Category: Drugs & Pharmacology Source Type: research
Delandistrogene Moxeparvovec: First Approval
This article summarizes the milestones in the development of delandistrogene moxeparvovec leading to this firs t approval in the USA for the treatment of ambulatory paediatric patients aged 4 through 5 years with DMD and a confirmed mutation in theDMD gene. (Source: Drugs)
Source: Drugs - August 11, 2023 Category: Drugs & Pharmacology Source Type: research
Ritlecitinib: First Approval
This article summarizes the milestones in the development of ritlecitinib leading to this first approval for severe alopecia areata. (Source: Drugs)
Source: Drugs - August 9, 2023 Category: Drugs & Pharmacology Source Type: research
Recent Advances in Antiarrhythmic Drug Therapy
AbstractCardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs (AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia management, despite moderate efficacy and the potential for significant adverse proarrhythmic effects. Due to conceptual, regulatory and financial considerations, the number of novel antiarrhythmic targets and agents in the development pipeline has decreased substantially during the last few decades. However, several promising candidates remain and there are exciting developments in repurposing and reformulating already existing drugs for indicat...
Source: Drugs - August 4, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Concizumab: First Approval
(Source: Drugs)
Source: Drugs - August 3, 2023 Category: Drugs & Pharmacology Source Type: research
Sulbactam/Durlobactam: First Approval
This article summarizes the milestones in the development of sulbactam/durlobactam leading to this first approval for the treatment of infections caused by ABC. (Source: Drugs)
Source: Drugs - July 31, 2023 Category: Drugs & Pharmacology Source Type: research
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn ’s Disease
In conclusion, to date, anti-TNFs are the most effective agents in preventing and treating POR in CD. Anti-TNFs remain an effective option to prevent POR also in patients with anti-TNF failure before surgery. Vedolizumab seems to be quite effective in the prevention of POR in patients with increased ri sk of recurrence. Ustekinumab is probably also effective in the postoperative setting, although the comparative efficacy with anti-TNFs or vedolizumab is still unclear. (Source: Drugs)
Source: Drugs - July 28, 2023 Category: Drugs & Pharmacology Source Type: research
Sovateltide: First Approval
This article summarizes the milestones in the development of sovateltide leading to this first approval for use in patients with ACIS. (Source: Drugs)
Source: Drugs - July 24, 2023 Category: Drugs & Pharmacology Source Type: research
